Table 1 Clinical studies in which predictive and prognostic roles of NLR, PLR, and LMR/MLR were evaluated in patients with LSCC
From: Role and research progress of hematological markers in laryngeal squamous cell carcinoma
Year | Author | Case | Object | Inflammatory markers | Cut-off value | Conclusion |
|---|---|---|---|---|---|---|
2014 | Kum et al. [32] | 209 | BLL, PLL, LSCC | NLR | - | NLR could be a useful inflammatory marker to differentiate LSCC from BLL and PLL |
2015 | Tu et al. [33] | 141 | LSCC | NLR | NLR: 2.17 | Elevated preoperative NLR was an independent predictor of poor prognosis for patients with LSCC after surgical resection |
2016 | Rachidi et al. [34] | 543 | HNSCC | NLR | - | NLR is a robust predictor of OS in oral, pharyngeal, and LSCC |
2016 | Wong et al. [35] | 140 | LSCC | NLR | - | Pre-treatment NLR may serve as a useful prognostic marker in LSCC |
2016 | Fu et al. [36] | 420 | LSCC undergoing total laryngectomy | NLR | NLR: 2.59 | The NLR may be an independent prognostic marker for CSS and OS in patients with advanced LSCC undergoing total laryngectomy |
2016 | Zeng et al. [37] | 125 | patients with locoregionally advanced LC (cT3–4 N0–3 M0) treated with chemoradiotherapy | NLR | NLR: 3.0 | Pre-treatment NLR is a useful prognostic marker in patients with locoregionally advanced LC treated with chemoradiotherapy |
2016 | Zhao et al. [38] | 202 | LC | NLR | NLR: 2.85 | Preoperative NLR level influences the recurrence and cervical lymph node metastasis of LC and can be considered a prognosis factor of LC |
2016 | Wang et al. [39] | 120 | undergone post-operativeradiotherapy for LSCC | NLR, PLR | NLR: 2.79 PLR: 112 | Markers of systemic and local inflammation, especially PLR was reliable prognostic factor in patients with LSCC |
2017 | Sumner et al. [40] | 196 | definitive treatment for cancers of the oropharynx or larynx | NLR | - | Higher pre-treatment NLR is prognostic of poor OS |
2017 | Kara et al. [31] | 81 | underwent surgery for LSCC | NLR, PLR | NLR: 2.04 PLR: 120.32 | Pre-treatment high PLR is predictive factors of a survival rates in patients with LSCC. The high PLR increases mortality in patients with LSCC. A high NLR may predict local recurrence and decrease PFS in patients with LSCC |
2017 | Wu et al. [41] | 405 | laryngeal lesions diagnosed by pathology | NLR, LMR | - | LMR and NLR as a systemic inflammatory index have a certain reference value to differentiate LSCC from PLL and BLL |
2017 | Hsueh et al. [42] | 979 | LSCC | NLR, PLR, LMR | NLR: 2.40 PLR: 111.00 LMR: 3.50 | Preoperative lymphocytes, NLR, PLR and LMR were significantly associated with cancer progression, DFS and CSS, and these hematological parameters could be considered independent prognostic values for patients with LSCC |
2018 | Du et al. [43] | 654 | LSCC | NLR | NLR: 3.18 | Pre-treatment NLR was associated with the prognostic outcomes for patients with laryngeal cancer, and may assist to establish prognostic factors for these patients |
2018 | Cho et al. [44] | 621 | definitive radiotherapy for nasopharyngeal, oropharyngeal, hypopharyngeal, and LC | NLR | NLR: 2.7 | Head and neck cancer tends to be more aggressive in patients with a high NLR, leading to a poorer outcome after radiotherapy |
2018 | Yilmaz et al. [45] | 144 | LC | NLR | - | NLR is a cheap and easily accessible marker which can be used as a prognostic faxtor in laryngeal cancer |
2018 | Zhong et al. [46] | 413 | T3-T4 LSCC | PLR | - | Change in PLR may serve as a useful prognostic predictor for patients with T3-T4 LSCC |
2018 | Mao et al. [47] | 899 | underwent laryngectomy for LSCC | PLR | PLR: 193.55 | Patients with PLR > 193.55 experience poor outcomes and represent malnutrition, more advanced cancer stage |
2018 | Chen et al. [48] | 361 | LSCC | NLR, PLR, MLR | NLR: 2.45 PLR: 114 MLR: 0.21 | The elevated preoperative NLR, PLR, MLR were significantly associated with worse survival and cancer progression. The preoperative NLR and postoperative MLR might be independent prognostic markers of OS and PFS in LSCC patients undergoing surgical resection |
2019 | Eskiizmir et al. [49] | 229 | Patients with benign, premalignant and malignant laryngeal neoplasms | NLR | NLR: 4 | Pre-treatment NLR is a useful and reliable predictive and prognostic biomarker for patients with laryngeal carcinoma |
2019 | Gorphe et al. [50] | 68 | T3 LC treated with induction chemotherapy using a preservation protocol | NLR | NLR: 5 | Patients treated with a preservation protocol, a high NLR, and anemia before induction chemotherapy were associated with shorter survival, independently of the response to chemotherapy |
2019 | Sheng et al. [51] | 110 | underwent surgical resection for LSCC | NLR | NLR: 2.22 | Preoperative increased NLR was associated with reduced prognosis in patients with LSCC |
2019 | Marchi et al. [52] | 113 | LSCC, CG | NLR, PLR | - | NLR and PLR are significantly increased in LSCC |
2019 | kucuk et al. [53] | 116 | previously operated LSCC | NLR, PLR | NLR: 2.79 PLR: 112 | No correlation was found between local and systemic inflammatory response |
2020 | Ye et al. [54] | 197 | oropharyngeal, hypopharyngeal and LC receiving multimodality treatment | NLR | NLR: 2.77 | Pre-treatment NLR elevation is promising predictor of prognosis in patients with operable HNSCC |
2020 | Cai et al. [55] | 203 | underwent surgery for LSCC | NLR, PLR | NLR: 2.41 PLR: 110.94 | NLR was valuable markers in predicting survival in patients with LSCC and may be used to inform clinicians in designing individual treatment strategies |
2020 | Chuang et al. [56] | 141 | hypopharyngeal cancer/LC | NLR, LMR | NLR: 2.95 LMR: 2.99 | Pretreatment NLR is superior to LMR in predicting treatment response and clinical outcomes among patients with laryngeal/hypopharyngeal cancer treated by chemoradiation/radiation |
2020 | Xun et al. [57] | 151 | undergone surgery for LSCC | NLR, PLR, MLR | NLR: 2.2 PLR: 106 MLR: 0.18 | Preoperative high NLR, PLR, and MLR were associated with poor prognosis |
2021 | Franz et al. [58] | 60 | treated with primary surgery for LSCC | NLR | NLR: 2.68 | NLR was shown to be significant in predicting DFS and recurrence risk |
2021 | Zhou et al. [59] | 180 | male LHSCC | PLR | PLR: 112.5 | Patients with LHSCC have abnormal high PLR, and a high pre-treatment PLR portends adverse survival |
2021 | Li et al. [60] | 147 | LSCC | NLR, PLR | NLR: 1.88 PLR: 117.36 | Preoperative NLR, PLR are promising prognostic predictors for patients with LSCC |
2021 | Akkas et al. [61] | 118 | LC | NLR, PLR | NLR: 3.8 PLR: 158 | High NLR, PRL have been identified as poor prognostic factors in DFS |
2021 | Sizer et al. [62] | 452 | BLL, PLL,MLL,CG | NLR, PLR | - | NLR, PLR were low in the CG and BLL groups and high in the MLL group |
2022 | Murad et al. [63] | 168 | LSCC | NLR | NLR: 2.02 | Pretreatment NLR ≥ 2.02 was an independent prognostic factor for poor OS. BMI can change the prognostic capacity of NLR in patients with LSCC |